Close Menu

NEW YORK (GenomeWeb) ­– Danaher announced Friday that it has completed its $4 billion acquisition of Cepheid.

Cepheid has been merged into Copper Merger Sub, a wholly owned subsidiary of Danaher, resulting in Cepheid becoming an indirect wholly owned subsidiary of Danaher.

Each outstanding share of Cepheid common stock was cancelled — except for shares held by Danaher, Copper Merger Sub, Cepheid, and respective subsidiaries — and converted into $53.00 per share in cash.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jun
04
Sponsored by
Ovation

This webinar will discuss the current status of COVID-19 testing, treatment and other aspects of the current pandemic as they relate to getting this outbreak under control.  

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.